The positive Part 1 safety data de-risks TLX591-Tx's combination profile and supports continued Phase 3 enrollment. Monitor FDA IND amendment decision and Part 2 enrollment updates as key catalysts. The differentiated liver-clearance mechanism could provide competitive advantage over existing PSMA RLTs if confirmed in larger randomized data.
TLX drugs
TLX drug pipeline →- ◆ ITM-11 4/10 Phase 3 (completed)
- ● TLX591-Tx 4/10 Phase 3
- ● Zircaix 4/10 Phase 3 (ZIRCON) completed; BLA under FDA review
- ▲ Gozellix 3/10 Approved (FDA, March 21, 2025 — NDA 219592, 505(b)(2))
- ● TLX101-Tx 3/10 Phase 3 (pivotal, just initiated); Phase 1 safety stage complete
- All TLX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 2 $9.16entry
- T+1 · 6mo ago −4.26%α −3.54% · $8.77
- T+5 · 5mo ago +2.73%α +5.69% · $9.41
- T+20 · 5mo ago +29.26%α +30.82% · $11.84
- T+60 · 3mo ago +21.51%α +20.39% · $11.13
Price Chart
How similar events traded
Executive Summary
Telix presented Phase 3 ProstACT Global Part 1 safety data at ASCO 2026 for TLX591-Tx in mCRPC, showing acceptable tolerability with standard-of-care combinations and no new safety signals. The data support advancing to Part 2 randomized expansion, with FDA engagement underway for U.S. enrollment. This is a positive clinical milestone for a first-in-class rADC candidate, but the stock impact is tempered by early-stage data and no near-term approval catalyst.
Key Facts
- Part 1 data from 36 patients showed acceptable safety across all SoC combination cohorts (abiraterone, enzalutamide, docetaxel) with no new safety signals.
- All 36 patients received both doses of TLX591-Tx per protocol; hematologic events (Grade 3-4 thrombocytopenia/neutropenia) were transient and consistent with class profile.
- Dosimetry showed radiation exposure to key organs well below established safety limits; highest absorbed dose in liver (1.62-5.08 mGy/MBq), low salivary gland uptake (0.001-0.104 mGy/MBq).
- Part 2 randomized 2:1 expansion is actively dosing in Australia, New Zealand, Canada, Turkey, UK, with approvals in China, Singapore, South Korea; FDA engagement underway for U.S. IND amendment.
- TLX591-Tx is a first-in-class lutetium rADC with differentiated pharmacology (liver clearance, minimal kidney/salivary toxicity) vs. existing PSMA-targeted small molecule RLTs.
Financial Impact
No financial data provided; TLX591-Tx has not received marketing authorization in any jurisdiction.
Risk Factors
- Part 2 randomized data (n~490) may not replicate Part 1 safety profile or show efficacy benefit vs. SoC alone.
- Regulatory delays in U.S. IND amendment could slow enrollment and timeline.
- Competition from approved PSMA-targeted RLTs (e.g., Pluvicto) with established commercial presence.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304754 |
Track record
27 reports on TLX
10 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +21.24% at T+60 after the May 18, 2026 report. 18 of 20 went positive at some point.
Filters
- Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
- Oct 20, 202627d ago 6-K Neutral 4/10 No price data
- Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
- Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
- Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
- Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
- Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
- Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers